Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/137217
Title: | The burden of latent multidrug-resistant tuberculosis |
Author: | García-Basteiro, Alberto L. Jenkins, Helen E. Rangaka, Moleboleng |
Keywords: | Tuberculosi Resistència als medicaments Tuberculosis Drug resistance |
Issue Date: | 4-Jul-2019 |
Publisher: | Elsevier Inc. |
Abstract: | In the past 10 years, there has been renewed interest in the early phases of the natural history of tuberculosis.1 Estimates suggest that around 25% of the world's population could have latent tuberculosis infection,2 5–10% of whom will develop active disease during their lifetime3 (10% annually among people with HIV).4 Failure to implement effective tuberculosis control measures to manage latent infection threatens elimination goals. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/S1473-3099(19)30271-3 |
It is part of: | Lancet Infectious Diseases , 2019 , vol. , num. , p. 0 |
URI: | http://hdl.handle.net/2445/137217 |
Related resource: | http://dx.doi.org/ 10.1016/S1473-3099(19)30271-3 |
ISSN: | 1473-3099 |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Garcia-BasteiroAL_Lancet_Infect_Dis_2019.pdf | 210.16 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License